Conclusion-Recommendation: Outpatients: Available data indicate against routine pharmacologic thromboprophylaxis in outpatients with COVID-19 in general. It is reasonable to suggest individualized thromboprophylaxis in outpatients at high risk for disease worsening (with adverse prognostic factors for severe disease, potential candidates for hospitalization or “hospital-at home programs”) and/or increased VTE risk after careful assessment of the bleeding risk. Regular assessment and reevaluation for disease worsening and bleeding risk is strongly recommended. Post-discharge:Post-hospital discharge prophylactic anticoagulation with rivaroxaban 10 mg once daily for approximately 1 month is recommended in high VTE risk patients if no drug-drug interactions are expected.